Aggarwal Pushkar
University of Cincinnati College of Medicine, 2545 Dennis Street Apt 7105, Cincinnati, Ohio, USA.
Ther Adv Drug Saf. 2019 Aug 18;10:2042098619869077. doi: 10.1177/2042098619869077. eCollection 2019.
Sugammadex is used for the reversal of neuromuscular blockade caused by rocuronium bromide and vecuronium bromide. As part of the post licensing phase of drug development, adverse events related to the use of sugammadex are still being uncovered and being reported. The potential association between sugammadex and adverse events bronchospasm and coronary arteriospasm using a retrospective pharmacovigilance signal analysis was carried out.
Food and Drug Administration's Adverse Event Reporting System database was used to run disproportionality analyses to investigate the potential association of sugammadex with bronchospasm or coronary arteriospasm. In this analysis we report the adverse event signal using frequentist methods of Relative reporting ratio (RRR), proportional reporting ratio (PRR), reporting odds ratio (ROR) and the Bayesian based Information Component metric.
A statistically significant disproportionality signal is found between sugammadex and bronchospasm ( = 44; chi-squared = 2993.87; PRR = 71.95 [95% CI: 54.00-95.85]) and sugammadex and coronary arteriospasm ( = 6; chi-squared = 209.39; PRR = 43.82 [95% CI: 19.73-97.33]) as per Evans criteria. Both statistically significant disproportionality signals persisted when stratified by gender. Based upon dynamic cumulative PRR graph, the PRR value has steadily increased and the 95% CI narrowed since December 2012.
The results of the pharmacovigilance analysis highlight a statistically significant disproportionality signal between sugammadex usage and bronchospasm and coronary arteriospasm adverse events. Physicians need to be aware of these adverse events when using sugammadex. The results of the pharmacovigilance signal analysis highlight a statistically significant disproportionality signal between sugammadex usage and bronchospasm and coronary arteriospasm adverse events. Physicians need to be aware of these adverse events when using sugammadex.
舒更葡糖钠用于逆转由罗库溴铵和维库溴铵引起的神经肌肉阻滞。作为药物研发上市后阶段的一部分,与舒更葡糖钠使用相关的不良事件仍在不断被发现和报告。采用回顾性药物警戒信号分析方法,对舒更葡糖钠与支气管痉挛和冠状动脉痉挛等不良事件之间的潜在关联进行了研究。
利用美国食品药品监督管理局不良事件报告系统数据库进行不成比例分析,以调查舒更葡糖钠与支气管痉挛或冠状动脉痉挛之间的潜在关联。在此分析中,我们采用频率法的相对报告率(RRR)、比例报告率(PRR)、报告比值比(ROR)以及基于贝叶斯的信息成分指标来报告不良事件信号。
根据埃文斯标准,在舒更葡糖钠与支气管痉挛(n = 44;卡方 = 2993.87;PRR = 71.95 [95%CI:54.00 - 95.85])以及舒更葡糖钠与冠状动脉痉挛(n = 6;卡方 = 209.39;PRR = 43.82 [95%CI:19.73 - 97.33])之间发现了具有统计学意义的不成比例信号。按性别分层时,这两个具有统计学意义的不成比例信号均持续存在。基于动态累积PRR图,自2012年12月以来,PRR值稳步上升,95%CI变窄。
药物警戒分析结果突出显示了舒更葡糖钠使用与支气管痉挛和冠状动脉痉挛不良事件之间具有统计学意义的不成比例信号。医生在使用舒更葡糖钠时需要注意这些不良事件。药物警戒信号分析结果突出显示了舒更葡糖钠使用与支气管痉挛和冠状动脉痉挛不良事件之间具有统计学意义的不成比例信号。医生在使用舒更葡糖钠时需要注意这些不良事件。